Vaxcyte
PCVX
251 hedge funds and large institutions have $8.13B invested in Vaxcyte in 2024 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 101 increasing their positions, 78 reducing their positions, and 18 closing their positions.
167% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 18
37% more call options, than puts
Call options by funds: $16.7M | Put options by funds: $12.2M
29% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 78
26% more capital invested
Capital invested by funds: $6.48B → $8.13B (+$1.65B)
13% more funds holding
Funds holding: 223 → 251 (+28)
1.44% more ownership
Funds ownership: 108.43% → 109.87% (+1.4%)
14% less funds holding in top 10
Funds holding in top 10: 14 → 12 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$160M |
| 2 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$150M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$142M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$89M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
+$85.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$33.5M |
| 2 |
VPC
Vestal Point Capital
New York
|
-$33M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$22.6M |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
-$19.9M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$19.8M |
PCVX Hedge Fund Activity: Q1 2024 in Review
251 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q1 2024, worth a combined $8.13B — up 26% from $6.48B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new PCVX positions and 18 closed out — a net gain of 30 holders — while 101 added to existing stakes and 78 trimmed.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $160M. The largest seller was Millennium Management, cutting an estimated $33.5M.
- 251 institutional investors held Vaxcyte (PCVX) as of Q1 2024, up from 223 in Q4 2023.
- Funds reported $8.13B of Vaxcyte stock for Q1 2024, up 26% quarter-over-quarter.
- 48 funds opened new Vaxcyte positions in Q1 2024 and 18 closed out, a net change of +30 holders.
- The largest Vaxcyte buyer in Q1 2024 was T. Rowe Price Investment Management, an estimated $160M added.
- The largest Vaxcyte seller in Q1 2024 was Millennium Management, an estimated $33.5M sold.
Based on aggregated 13F filings for Q1 2024.